

## NKR 22: Høfeber og allergisk helårssnue (allergisk rhinoconjunctivitis), PICO 8: Allergen-spezifisk immunterapi, børn og astma.

### Review information

#### Authors

Sundhedsstyrelsen<sup>1</sup>

<sup>1</sup>[Empty affiliation]

Citation example: S. NKR 22: Høfeber og allergisk helårssnue (allergisk rhinoconjunctivitis), PICO 8: Allergen-spezifisk immunterapi, børn og astma.. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

### Characteristics of studies

#### Characteristics of included studies

##### *Niggemann 2006*

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p> <p><b>Open Label:</b> YES</p> <p><b>Cluster RCT:</b></p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>SIT Control</p> <p><b>Included criteria:</b> clinical history of rhinitis, Birch or grass pollen season or both positive skin prick test Birch, grass or both positive conjunctival provocation, bric, grass or both</p> <p><b>Excluded criteria:</b> other clinical inhalation allergies previous SIT asthma symptoms and need for daily treatment</p>
<b>Interventions</b>	<p><b>Intervention Characteristics</b></p> <p>SIT Control</p>

<b>Outcomes</b>	<p><i>Continuous:</i></p> <ul style="list-style-type: none"> <li>● Rhinitis symptoms Mean VAS</li> </ul> <p><i>Dichotomous:</i></p> <ul style="list-style-type: none"> <li>● Development of asthma YES</li> <li>● Development of asthma NO</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b>  <b>Country:</b> Germany  <b>Setting:</b>  <b>Comments:</b>  <b>Authors name:</b> Niggemann B  <b>Institution:</b> Department of pediatric pneumology and immunology, Charité, Berlin  <b>Email:</b>  <b>Address:</b></p>
<b>Notes</b>	<p><b>Identification:</b>  <b>Participants:</b>  <b>Study design:</b>  <b>Baseline characteristics:</b>  <b>Intervention characteristics:</b>  <b>Pretreatment:</b>  <i>Kirsten Skamstrup Hansen</i> only data on data from all 6 centres at baseline time point '0'  <b>Continuous outcomes:</b>  <b>Dichotomous outcomes:</b>  <b>Adverse outcomes:</b></p>

**Risk of bias table**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: not stated
Allocation concealment (selection bias)	Unclear risk	Comment: concealment not stated stratification for relevant parameters included

Blinding of participants and personnel (performance bias)	High risk	Comment: unblinded study
Blinding of outcome assessment (detection bias)	Unclear risk	Comment: unblinded study no data on whether the data management was performed blinded
Incomplete outcome data (attrition bias)	Low risk	Comment: No data but very few drop-outs.
Selective reporting (reporting bias)	Unclear risk	Comment: unblinded study no data on excluded patients no data on side-effects?
Other bias	Unclear risk	Comment: relatively small groups

*Footnotes*

**Characteristics of excluded studies**

*Footnotes*

**Characteristics of studies awaiting classification**

*Footnotes*

**Characteristics of ongoing studies**

*Footnotes*

**Summary of findings tables**

**References to studies**

**Included studies**

***Niggemann 2006***

Niggemann, B.; Jacobsen, L.; Dreborg, S.; Ferdousi, H. A.; Halken, S.; Host, A.; Koivikko, A.; Koller, D.; Norberg, L. A.; Urbanek, R.; Valovirta, E.; Wahn, U.; Moller, C.; PAT Investigator, Group. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.. Allergy 2006;61(7):855-859. [DOI: ALL1068 [pii]]

**Excluded studies**


**Data and analyses**

**1 Immune therapy vs Control**

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Rhinitis symptomscorer (Rhinitis symptoms score)	1	183	Mean Difference (IV, Fixed, 95% CI)	-14.10 [-32.17, 3.97]
1.1.1 Symptom score, Change values, 2 years termination of treatment	1	183	Mean Difference (IV, Fixed, 95% CI)	-14.10 [-32.17, 3.97]
1.2 Udvikling af astma (Development of asthma)	1		Risk Ratio (IV, Fixed, 95% CI)	No totals
1.2.1 5 year follow-up	1		Risk Ratio (IV, Fixed, 95% CI)	No totals

**Figures**

**Figure 1 (Analysis 1.1)**



Forest plot of comparison: 1 Immune therapy vs Control, outcome: 1.1 Rhinitis symptomscorer (Rhinitis symptoms score).

**Figure 2 (Analysis 1.2)**

Study or Subgroup	Immune therapy		Total	Events	Control	Total	Risk Ratio IV, Fixed, 95% CI	Risk Ratio IV, Fixed, 95% CI	Risk of Bias														
	Events	Total							A	B	C	D	E	F	G								
1.2.1 5 year follow-up																							
Niggemann 2006	15	75	29	67	67	0.46	[0.27, 0.78]								?	?	?	?	?	?	?		

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Immune therapy vs Control, outcome: 1.2 Udvikling af astma (Development of asthma).